Impact of Malaria at The End of Pregnancy On Infant Mortality and Morbidity
Impact of Malaria at The End of Pregnancy On Infant Mortality and Morbidity
Impact of Malaria at The End of Pregnancy On Infant Mortality and Morbidity
Centre for International Health Research and Department of Pathology, Hospital Clinic, Institut d'Investigacions Biome`dicas August Pi i
Sunyer, Universitat de Barcelona, Spain; 2Manhic
xa Health Research Centre, Mozambique; 3National Institute of Health, Ministry of Health, Maputo,
Mozambique; and 4National Directorate of Health and National Malaria Control Program, Ministry of Health, Maputo, Mozambique.
Background. There is some consensus that malaria in pregnancy may negatively affect infants mortality and
malaria morbidity, but there is less evidence concerning the factors involved.
Methods. A total of 1030 Mozambican pregnant women were enrolled in a randomized, placebo-controlled
trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, and their infants were followed up
throughout infancy. Overall mortality and malaria morbidity rates were recorded. The association of maternal and
fetal risk factors with infant mortality and malaria morbidity was assessed.
Results. There were 58 infant deaths among 997 live-born infants. The risk of dying during infancy was
increased among infants born to women with acute placental infection (odds ratio [OR], 5.08 [95% confidence
interval (CI), 1.7714.53)], parasitemia in cord blood (OR, 19.31 [95% CI, 4.4484.02]), low birth weight (OR, 2.82
[95% CI, 1.276.28]) or prematurity (OR, 3.19 [95% CI, 1.148.95]). Infants born to women who had clinical
malaria during pregnancy (OR, 1.96 [95% CI, 1.133.41]) or acute placental infection (OR, 4.63 [95% CI, 2.10
10.24]) had an increased risk of clinical malaria during infancy.
Conclusions. Malaria infection at the end of pregnancy and maternal clinical malaria negatively impact survival
and malaria morbidity in infancy. Effective clinical management and prevention of malaria in pregnancy may
improve infants health and survival.
691
Bardaj et al.
The study was carried out as part of a randomized placebocontrolled trial of intermittent preventive treatment with
sulfadoxine-pyrimethamine and long-lasting insecticide-treated
bed nets for malaria prevention in pregnancy (trial registration
number: NCT00209781) [31]. A total of 1030 women were
enrolled into the trial at the ANC of the MDH from August 2003
to April 2005, after giving informed consent. There were 1004
live-born infants (501 in the sulfadoxine-pyrimethamine group,
503 in the placebo group); 7 were lost to follow-up owing to
migration (3 in the placebo group, 3 in the sulfadoxine-pyrimethamine group) or refusal (1 in the sulfadoxinepyrimethamine group), resulting in a total of 997 live-born
infants that were followed up until 12 months of life and
included in this analysis.
An ongoing clinical surveillance system established at the
MDH covers all pediatric outpatient and inpatient visits up to 14
years of age. At each consultation, a standardized questionnaire,
recording demographic and clinical data, is completed for each
attending child. Blood films are prepared for malaria parasite
examination, and the hematocrit is measured if there is a history
of fever in the preceding 24 h or if the axillary temperature was
>37.5C. Clinical malaria episodes are treated according to
national guidelines [32]. During the study, a clinical surveillance
system was also established at the MDH maternity clinic for all
pregnant and puerperal women attending with clinical complaints. Study personnel recorded demographic, obstetric,
and clinical information. A capillary blood sample for parasitemia examination and anemia screening was collected if
a woman reported clinical symptoms suggestive of malaria. All
women were offered voluntary counselling and testing for HIV,
and those testing positive and their children were given prophylaxis with nevirapine and referred for adequate clinical
follow-up.
At delivery, blood samples were collected from the mother
and the umbilical cord for hematological and parasitological
determinations. Placental blood and tissue samples were also
collected for malaria infection examination. A capillary blood
sample was collected from the mother and the infant for parasitological and hematological determinations 8 weeks after delivery. Twelve months after birth a capillary blood sample from
the infant was obtained for parasitological and hematological
assessment. Deaths occurring during the follow-up period were
Infant Mortality
Maternal Factor
Yes
No
Yes
No
(n 5 58)
(n 5 939)
(n 5 58)
(n 5 939)
No.
(%)
No.
(%)
Gravidity
.422
Primigravid
19
(7.5)
237
(92.5)
13 pregnancies
22
(5.5)
373
(94.5)
>4 or pregnancies
17
(5)
329
(95)
HIV test
Negative
31
(5)
614
(95)
Positive
21
(11)
176
(89)
(4)
149
(96)
Unknownb
35
(7)
465
(93)
Sulfadoxine-pyrimethamine
23
(5)
474
(95)
(10)
104
(90)
Negative
Literacy
46
(5)
835
(95)
20
(5)
390
(95)
38
(6.5)
546
(93.5)
(100)
(0)
Malaria episodes
during pregnancy
(5)
860
(95)
Yes
10
(11)
79
(89)
P valuea
.436
34
(7)
479
(93)
Female
Unknown
24
0
(5)
(0)
456
4
(95)
(100)
37
(4)
870
(96)
,.001
Yes
10
(25)
30
(75)
Unknown
11
(22)
39
(78)
No
37
(4)
835
(96)
Yes
Unknown
19
2
(16)
(10.5)
,.001
97
17
(84)
(89.5)
.378
No
45
(6)
719
(94)
Yes
(9)
63
(91)
Unknown
(4)
157
(96)
46
(6)
779
(94)
48
(%)
.031
No
No.
.446
(%)
Male
No
.034
Positive
No.
Premature delivery
.136
Placebo
Fetal Outcome
Sex of newborn
.009
Intervention group
Unknown
P valuea
Thick and thin blood smears were Giemsa stained and read with
a light microscope to quantify parasitemia according to standard, quality-controlled procedures [27, 33]. To identify maternal and infant anemia, hematocrits were read in a Hawksley
hematocrit reader (Hawksley & Sons) after centrifuge in a microhematocrit centrifuge. Maternal HIV status was assessed
using the Determine HIV-1/2 Rapid Test (Abbott Laboratories) and positive results were confirmed by the Uni-Gold
Rapid Test (Trinity Biotech). Syphilis screening was performed with the rapid plasma reagin test, (Syphacard, Wellcome). Placental biopsies and impression smears from
placental blood were processed and read according to standard procedures [34, 35].
Statistical Methods and Definitions
.002
4
(44)
(56)
Unknown
Placental malariab
(5)
155
(95)
Not infected
20
(5)
404
(95)
Past infection
.008
18
(6)
303
(94)
Acute infection
(17)
35
(83)
Chronic infection
(11)
73
(89)
Unknown
(3)
124
(97)
NOTE.
Unadjusted P value (Fishers exact test).
b
Past infection was defined as the presence of malaria pigment but not
parasites; acute infection, as the presence of malaria parasites and minimal
pigment; and chronic infection, as the presence of malaria parasites and
pigment.
693
censoring by withdrawal, whichever occurred first, was estimated using Cox regression models. Data analysis was performed using Stata 11 software (Stata).
Maternal clinical malaria was defined as P. falciparum asexual
parasitemia of any density in a peripheral blood slide plus any
signs and/or symptoms suggestive of malaria disease, such as
referred history of fever in the last 24 h, fever (axillary temperature, >37.5C), pallor, arthromyalgias, headache, or history of
convulsions. The definition of clinical malaria in infants used in
the passive morbidity surveillance was presence of fever (axillary
temperature, >37.5C) or a history of fever in the preceding
24 h plus a P. falciparum asexual parasitemia of any density on
a blood slide. The duration of a malaria episode was estimated as
28 days to avoid counting the same episode twice. Subjects were
not considered at risk during the 28 days after an episode and
did not contribute to either the denominator or the numerator
during this period. Fetal anemia was defined as a hematocrit
level in cord blood ,37%. According to a previous definition
based on histological examination, placental infection was
classified as past (presence of malaria pigment only), acute
(presence of parasites and minimal pigment), or chronic
(presence of malaria parasites and pigment). Active infection
includes both acute and chronic infection [36].
(95% CI)
HIV test
1
Positive
2.59
(1.354.98)
Unknownb
0.64
(0.231.82)
.087
No
Yes
2.14
(0.905.10)
Premature delivery
No
Yes
Unknown
,.001
1
3.19
(1.148.95)
29.82
(9.9789.21)
.012
1
2.82
(1.276.28)
19.94
.077
No
Yes
1
1.07
(0.392.90)
Unknown
0.04
(0.000.69)
,.001
1
19.31
(4.4484.02)
6.57
(.6368.64)
Placental malariac
Table 1 and Table 2 show the crude analysis of maternal and fetal
factors respectively and their association with infant mortality.
Maternal HIV status (21/197 [11%] vs 31/645 [5%]; P 5 .009),
a positive rapid plasma reagin test (12/116 [10%] vs 46/881
[5%]; P 5 .034)], and clinical malaria episodes during pregnancy (10/89 [11%] vs 48/908 [5%]; P 5 .031) were all significantly associated with an increased risk of dying during infancy.
Premature delivery (10/40 [25%] vs 37/907 [4%]; P , .001),
low birth weight (19/116 [16%] vs 37/872 [4%]; P , .001), cord
blood parasitemia (4/9 [44%] vs 46/825 [6%]; P 5 .002), and
acute placental malaria infection (7/42 [17%]; P 5 .008) were
also associated with an increased risk of infant mortality.
Multivariate Analysis of Maternal and Fetal Factors and
Association with Infant Mortality
Bardaj et al.
P value
.005
Negative
Not infected
RESULTS
OR
.012
Not infected
Past infection
1
1.12
(.532.33)
Acute infection
5.08
(1.7714.53)
Chronic
1.55
(.594.04)
Unknown
0.25
(.041.83)
Intervention group
.189
Placebo
Sulfadoxine-pyrimethamine
0.44
(.131.49)
NOTE. a Factors included in the models are those shown in Table 1 and
Table 2. CI, confidence interval; HIV, human immunodeficiency virus; OR, odds
ratio.
b
Refused voluntary counseling and testing.
c
Past infection was defined as the presence of malaria pigment but not
parasites; acute infection, as the presence of malaria parasites and minimal
pigment; and chronic infection, as the presence of malaria parasites and pigment.
blood parasitemia was also significantly associated with an increased risk of infant mortality (OR, 19.31 [95% CI, 4.4484.02];
P , .001]. There were more infant deaths among women who
had an episode of clinical malaria during pregnancy, although
this difference was of borderline statistical significance (OR, 2.14
[95% CI, 0.905.10]; P 5 .087].
Interestingly, when just the postneonatal period was considered, the risk of death was also higher among infants born to
women who had acute placental infection (OR, 5.79 [95% CI,
1.8118.51]; P , .019), parasites in the cord blood (OR, 21.30
[95% CI, 3.56127.36]; P , .003), or clinical malaria during
gestation (OR, 2.84 [95% CI, 1.037.86]; P , .045).
This study builds on previous evidence showing a negative impact of malaria infection during pregnancy on the risk to malaria
in the infant [21, 23, 37]. It also confirms the inconclusive evidence on the negative effect of maternal infection on infants
survival [1820].
The detailed placental examination done in this study revealed that placental infections occurring at the end of pregnancy are those most likely to have an impact on infants
survival. This is supported by the independent, significant association of both acute placental infection (parasites with or
without minimal pigment deposition) and cord blood parasitemia with an increase in the infants risk of death. The inflammatory changes associated with malaria infection in the
placenta may compromise the transfer of metabolic and nutrient
factors, as well as fetal oxygen supply, all of which may negatively
affect the developing fetus [3942]. In addition, it has been
reported that placental malaria is associated with a reduction in
the placental transfer of antibodies [43, 44]. This may affect the
immune status of the newborn and thus make the infant more
vulnerable to infectious diseases [45, 46]. The latter could explain why the effect of acute placental malaria seems to extend
beyond the neonatal period.
Little is known of the actual impact of congenital malaria,
defined as the presence of cord blood parasitemia, on the infants health in endemic areas other than an increased frequency
of anemia a few months after birth [47]. Cord blood parasitemia
is usually of low density, but it may be more frequent than
previously thought, as is shown when molecular techniques
are used for parasite detection [48]. Malaria parasites may
cross the placenta either during pregnancy or at the time of
delivery. Vertical transmission of malaria is likely to have
important implications for fetal and newborn development.
Direct infection of the fetus may be associated with preterm
delivery and fetal growth restriction or could increase
the likelihood of stillbirth. Fetal exposure to blood-stage
malaria antigens may also have profound long-term effects
during infancy by priming the immune responses of the fetus,
inducing immune tolerance, or both [24, 48]. Depending on
the effect on the fetal immune system, exposure to the
DISCUSSION
695
OR
(95% CI)
Multivariate Model
P value
OR
(95% CI)
.030
.017
Negative
Positive
0.56
(0.340.93)
.50
(0.300.85)
Unknownb
0.61
(0.351.10)
0.62
1
(0.351.10)
.001
No
Yes
2.40
.016
1
(1.453.98)
1.96
(1.133.41)
.028
1
.008
1
1.21
(0.344.30)
1.40
(0.375.31)
0.50
(0.290.83)
0.43
(0.250.74)
Placental malariac
,.001
Not infected
Past infection
,.001
1
3.43
(2.205.33)
3.06
(1.944.82)
Acute infection
4.20
(1.949.12)
4.63
(2.1010.24)
Chronic infection
Unknown
3.82
0.90
(2.067.08)
(0.421.93)
3.95
0.88
(2.077.55)
(0.411.92)
Gravidity
.199
Primigravid
13 pregnancies
0.71
>4 pregnancies
0.70
.
.
(0.461.09)
(0.451.09)
.
.
.
.
Intervention group
.166
Placebo
Sulfadoxine-pyrimethamine
Rapid plasma reagin syphilis test
1.28
(0.901.83)
.551
Positive
Negative
1.17
(0.691.99)
Literacy
.608
1.10
(0.771.58)
Sex of newborn
.288
Male
Female
1
1.21
(0.851.72)
Premature delivery
.380
No
Yes
0.81
(0.31-2.10)
Unknown
0.49
(0.171.39)
.581
No
Yes
Fetal anemia (hematocrit, ,37%)
1.16
(0.681.96)
.019
No
Yes
0.88
(0.441.77)
Unknown
0.41
(0.220.76)
.020
No
Yes
0.66
(0.085.29)
Unknown
0.42
(0.230.77)
P value
NOTE.
Factors included in the models are those shown in Table 1 and Table 2. CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
b
Refused voluntary counseling and testing.
c
Past infection was defined as the presence of malaria pigment but not parasites; acute infection, the presence of malaria parasites and minimal pigment; and
chronic infection, the presence of malaria parasites and pigment.
696
Bardaj et al.
Figure 1. Time to first or only clinical malaria episode in infants born to women with placental malaria compared with those born to women without
placental malaria, by parity. Infants born to women of all parities (A), primigravid women (B), women with 13 previous pregnancies (C), and women
with >4 previous pregnancies (D). P values adjusted by season: ,.001 (primigravid women), .014 (13 previous pregnancies), ,.001 (>4 pregnancies),
and ,.001 (all gravidities). P values adjusted by previous malaria episodes during pregnancy: .002 (primigravid women), ,.026 (13 previous
pregnancies), ,.001 (>4 pregnancies), and ,.001 (all gravidities).
697
References
1. United Nations. The Millennium Development Goals report. 2010.
2. Statistical Annex. United Nations. The Millennium Development Goals
report 2009. MDG Indicators Database.
3. Hamer DH, Mwanakasale V, Macleod WB, et al. Two-dose versus
monthly intermittent preventive treatment of malaria with sulfadoxinepyrimethamine in HIV-seropositive pregnant Zambian women. J Infect
Dis 2007; 196:158594.
4. Black RE, Morris SS, Bryce J. Where and why are 10 million children
dying every year? Lancet 2003; 361:222634.
698
Bardaj et al.
27. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A
vaccine against Plasmodium falciparum infection and disease in young
African children: randomised controlled trial. Lancet 2004; 364:
141120.
28. Nhacolo AQ, Nhalungo DA, Sacoor CN, Aponte JJ, Thompson R,
Alonso P. Levels and trends of demographic indices in southern rural
Mozambique: evidence from demographic surveillance in Manhica
district. BMC Public Health 2006; 6:291.
29. Documento estrategico para o controlo e combate da Malaria em
Moc
xambique, 2006- 2009. Programa Nacional de Controlo de Malaria.
Ministerio da Saude de Moc
xambique Maputo, 2006.
30. Programa Nacional de Controlo de ITS/HIV/SIDA. Plano estrategico
nacional de combate a`s ITS/HIV/SIDA do Ministerio da Saude 20042008. Maputo, Mozambique: Ministerio da Saude, 2004.
31. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebocontrolled trial of intermittent preventive treatment in pregnant
women in the context of insecticide treated nets delivered through the
antenatal clinic. PLoS ONE 2008; 3:e1934.
32. Guinovart C, Bassat Q, Sigauque B, et al. Malaria in rural Mozambique.
I. Children attending the outpatient clinic. Malar J 2008; 7:36.
33. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy
of SPf66 vaccine against Plasmodium falciparum malaria in children in
southern Tanzania. Lancet 1994; 344:117581.
34. Ordi J, Ismail MR, Ventura PJ, et al. Massive chronic intervillositis of
the placenta associated with malaria infection. Am J Surg Pathol 1998;
22:100611.
35. Rogerson SJ, Mkundika P, Kanjala MK. Diagnosis of Plasmodium falciparum malaria at delivery: comparison of blood film preparation
methods and of blood films with histology. J Clin Microbiol 2003;
41:13704.
36. Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria:
a histological, immunohistochemical, and quantitative study. Hum
Pathol 2000; 31:8593.
37. Mutabingwa TK, Bolla MC, Li JL, et al. Maternal malaria and gravidity
interact to modify infant susceptibility to malaria. PLoS Med 2005; 2:e407.
699